It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

An Efficacy and Safety Trial of MK-8931 in Subjects with Prodromal Alzheimer’s Disease

Clinical Trial Title: 
An Efficacy and Safety Trial of MK-8931 in Subjects with Prodromal Alzheimer’s Disease
Clinical Trial Protocol ID: 
13092401
Clinical Trial Investigator Name: 
Raj C. Shah, MD
Clinical Trial Protocol Description: 

The purpose of this four-year study is to evaluate the efficacy and safety of multiple doses of an experimental drug compared to placebo, as measured by overall clinical decline and/or progression, in subjects with prodromal AD. At Rush University Medical Center, we anticipate recruiting approximately five people. Treatment or matching placebo will be assigned randomly.

Clinical Trial Eligibility Criteria: 

In order to participate you must have:
• Are 50 to 85 years of age
• Have been diagnosed with prodromal Alzheimer’s disease or aMCI
• Have a study partner willing to accompany you to all study visits

You will be excluded from the study if  you:
• Are unwilling or unable to undergo multiple PET or MRI scans
• Have medical conditions that are not stable or that require adjustments of your medications

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Alzheimer’s Disease and Related Dementias
Contact Phone: 
(312) 942-3033
Contact Name: 
Pat Samuels